Misplaced Pages

Mitiperstat

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Pharmaceutical compound
Mitiperstat
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 1--4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolopyrimidin-4-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC15H15ClN4OS
Molar mass334.82 g·mol
3D model (JSmol)
SMILES
  • C(C1=C(C=CC(=C1)Cl)CN2C3=C(C(=O)NC2=S)NC=C3)N
InChI
  • InChI=1S/C15H15ClN4OS/c1-8(17)11-6-10(16)3-2-9(11)7-20-12-4-5-18-13(12)14(21)19-15(20)22/h2-6,8,18H,7,17H2,1H3,(H,19,21,22)/t8-/m1/s1
  • Key:BHKKSKOHRFHHIN-MRVPVSSYSA-N

Mitiperstat (AZD4831) is an irreversible inhibitor of myeloperoxidase and experimental drug in development for heart failure with preserved ejection fraction. It is being developed by AstraZeneca.

References

  1. Michaëlsson, Erik; Lund, Lars H.; Hage, Camilla; Shah, Sanjiv J.; Voors, Adriaan A.; Saraste, Antti; Redfors, Björn; Grove, Erik L.; Barasa, Anders; Richards, A. Mark; Svedlund, Sara; Lagerström-Fermér, Maria; Gabrielsen, Anders; Garkaviy, Pavlo; Gan, Li-Ming; Lam, Carolyn S.P. (July 2023). "Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF". JACC: Heart Failure. 11 (7): 775–787. doi:10.1016/j.jchf.2023.03.002. PMID 37140510. S2CID 258485391.
  2. Lam, Carolyn S.P.; Lund, Lars H.; Shah, Sanjiv J.; Voors, Adriaan A.; Erlinge, David; Saraste, Antti; Pirazzi, Carlo; Grove, Erik L.; Barasa, Anders; Schou, Morten; Aziz, Ahmed; Svedlund, Sara; Wijngaarden, Jan Van; Lindstedt, Eva-Lotte; Gustavsson, Andreas; Nelander, Karin; Garkaviy, Pavlo; Gan, Li-Ming; Gabrielsen, Anders (April 2023). "Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results". Journal of Cardiac Failure. doi:10.1016/j.cardfail.2023.04.003. PMID 37072105. S2CID 258184680.
  3. Bhattacharya, Chandrali; Sandinge, Ann-Sofie; Bragg, Ryan A.; Heijer, Maria; Yan, Jingjing; Andersson, Linda C.; Jurva, Ulrik; Pelay-Gimeno, Marta; Vaes, Wouter H.J.; de Ligt, Rianne A.F.; Gränfors, Malin; Amilon, Carl; Lindstedt, Eva-Lotte; Menakuru, Somasekhara R.; Garkaviy, Pavlo; Weidolf, Lars; Gopaul, V. Sashi (April 2023). "Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans". Drug Metabolism and Disposition. 51 (4): 451–463. doi:10.1124/dmd.122.001100. PMID 36639243. S2CID 255800825.
  4. Jurva, Ulrik; Weidolf, Lars; Sandinge, Ann-Sofie; Leandersson, Carina; Ekdahl, Anja; Li, Xue-Qing; Antonsson, Thomas; Sundell, Johan; Westerlund, Kristina; Amilon, Carl; Inghardt, Tord; Gopaul, V. Sashi (April 2023). "Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans". Drug Metabolism and Disposition. 51 (4): 464–479. doi:10.1124/dmd.122.001099. PMC 11022936. PMID 36653117. S2CID 255972963.
  5. Nelander, Karin; Lagerstrom‐Fermer, Maria; Amilon, Carl; Michaëlsson, Erik; Heijer, Maria; Kjaer, Magnus; Russell, Muir; Han, David; Lindstedt, Eva‐Lotte; Whatling, Carl; Gan, Li‐Ming; Ericsson, Hans (May 2021). "Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction". Clinical and Translational Science. 14 (3): 812–819. doi:10.1111/cts.12859. PMC 8212712. PMID 32770730.
  6. Gan, Li‐Ming; Lagerström‐Fermér, Maria; Ericsson, Hans; Nelander, Karin; Lindstedt, Eva‐Lotte; Michaëlsson, Erik; Kjaer, Magnus; Heijer, Maria; Whatling, Carl; Fuhr, Rainard (April 2019). "Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers". British Journal of Clinical Pharmacology. 85 (4): 762–770. doi:10.1111/bcp.13855. PMC 6422671. PMID 30618054.
  7. Inghardt, Tord; Antonsson, Thomas; Ericsson, Cecilia; Hovdal, Daniel; Johannesson, Petra; Johansson, Carina; Jurva, Ulrik; Kajanus, Johan; Kull, Bengt; Michaëlsson, Erik; Pettersen, Anna; Sjögren, Tove; Sörensen, Henrik; Westerlund, Kristina; Lindstedt, Eva-Lotte (8 September 2022). "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction". Journal of Medicinal Chemistry. 65 (17): 11485–11496. doi:10.1021/acs.jmedchem.1c02141. PMC 9469207. PMID 36005476.
  8. "AstraZeneca's investigational MPO inhibitor AZD4831 shows promise in patients with heart failure and a preserved ejection fraction". AstraZeneca. July 2021. Retrieved 11 November 2023.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: